Related Experiment Video
Updated: Oct 4, 2026

One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure
Published on: June 25, 2010
Neonatal screening and long-term follow-up of phenylketonuria: the French database
V Abadie1, J Berthelot, F Feillet
1Service de Pédiatrie Générale, Hôpital Necker-Enfants Malades, Paris, France.
Insights
Phenylketonuria (PKU) screening in France has been effective since 1966, demonstrating a stable incidence and improved patient outcomes. Early diagnosis and dietary management are crucial for successful long-term results in PKU patients.
Area of Science:
- Medical screening programs
- Pediatric metabolic disorders
- Public health initiatives
Background:
- Neonatal screening for phenylketonuria (PKU) initiated in France in 1966.
- A national association established in 1978 to manage the screening program and patient follow-up.
Purpose of the Study:
- Evaluate the French PKU screening program's effectiveness.
- Assess hyperphenylalaninaemia epidemiology, screening efficacy, patient management, and outcomes.
Main Methods:
- Utilized a national database compiled from physician questionnaires and a 1994 inquiry.
- Investigated diagnosis, treatment, and school outcomes for all French PKU patients.
Main Results:
- PKU diagnosed in 81.6% of hyperphenylalaninaemia (HPA) cases; incidence stable at 1:17,124 births since 1980.
- Screening sensitivity reached 99.3%; median age at diet initiation decreased to 14 days by 1996.
- Diet discontinuation age increased from 6 years (pre-1990) to 8-10 years, correlating with better school outcomes.
Conclusions:
- Nationwide organized screening programs are beneficial for PKU management.
- Early neonatal diagnosis and timely diet initiation are vital for PKU patients.
- Extended strict dietary adherence in childhood improves patient outcomes.
Background:
In France, neonatal screening of phenylketonuria (PKU) started in 1966. A national association was created in 1978 in order to organise the neonatal screening program and to control the efficacy of the screening and patients' follow-up.
Aims:
To evaluate the results of the French PKU screening program in terms of hyperphenylalaninaemia epidemiology, efficacy of the screening procedure, management and outcome of the patients.
Study Design:
The national database has been filled-up first with the answers to questionnaires that were sent each year by the PKU patients' physicians, and second with the results of an additional inquiry, which was set up in 1994 in order to investigate diagnosis, treatment, and school outcome of all French PKU patients.
Results:
PKU was diagnosed in 81.6% of patients with hyperphenylalaninaemia (HPA), non-PKU HPA in 17.2% and cofactor deficiency in 1.1%. From 1980, incidence of PKU has been stable: 1 per 17,124 live births. Sensitivity of the screening procedure was 99.3%. Age at diet initiation regularly decreased to reach 14 days as a median in 1996. Until 1990, median age at diet discontinuation was 6 years of age. Later, strict diet was continued longer (at least, up to 8-10 years). PKU patients who entered to secondary school at normal age were characterised by an earlier age at diagnosis and at diet initiation and a later age at diet discontinuation, compared to those who entered 1 year or more behind normal age.
Conclusion:
These data confirm the benefit of a nationwide organised screening program. They emphasise the importance of an early neonatal diagnosis and diet initiation in PKU patients and are consistent with the benefit of a longer period of strict diet in childhood.
Related Concept Videos
Inborn Errors of Metabolism
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
